Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Clinical trial NCT06015568 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06015568
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-01
- Primary completion
- 2028-11-04
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.